BIGG yields 2000000.00% · ABBV yields 3.06%● Live data
📍 BIGG pulled ahead of the other in Year 1
Combined, BIGG + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BIGG + ABBV for your $10,000?
Big Tree Group, Inc. engages in sourcing, contractual manufacturing, distributing, and exporting toys and related products. It sources various toys that are made of plastic, wood, metal, wool, and electronic materials primarily targeting children from infants to teenagers. The company offers infant appliances, games, balls, dolls, stuffed toys, transformers, racing track sets, play sets, water toys, and educational toys that could be operated by battery, manual power, wire control, remote control, voice control, infrared ray control, and other applications, as well as offers Big Tree Magic Puzzle (3D) products. It also provides 28/game stations, magician gears, toys, chesses, sport balls, fitness apparatus, exercise instruments, swimming pools, and roller skates, as well as adornments for the Christmas tree under the Big Tree Carnival and Big Tree brands. The company offers its sourcing services to distributors, trading companies, and wholesalers primarily located in mainland China, Hong Kong, Europe, South America, Asia and the United States; and Big Tree Magic Puzzle (3D) directly to consumers in China through its showrooms and airport locations, as well as through its Tmall.com online store. Big Tree Group, Inc. was founded in 2003 and is headquartered in Shantou, China. Big Tree Group, Inc. is a subsidiary of Lins (HK) International Trading Limited.
Full BIGG Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.